FDA.reportPublic FDA data

Adzenys 6.3 MG 24 HR Extended Release Distintegrating Oral Tablet

RxCUI
1739833
RxNorm name
Adzenys 6.3 MG 24 HR Extended Release Distintegrating Oral Tablet
Display name
Adzenys 6.3 MG 24 HR Extended Release Distintegrating Oral Tablet
Full name
Adzenys 6.3 MG 24 HR Extended Release Distintegrating Oral Tablet
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:39:19

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
c1179269-00b5-48ea-972d-31e614e99b7eAdzenys XR-ODT 6.3 MG 24HR Extended Release Distintegrating Oral Tablet [PSN] · 24 HR amphetamine 6.3 MG Extended Release Oral Tablet [Adzenys] [SBD] · Adzenys 6.3 MG 24 HR Extended Release Distintegrating Oral Tablet [SY]315These highlights do not include all the information needed to use ADZENYS XR-ODT™ safely and effectively. See full prescribing information for ADZENYS XR-ODT. ADZENYS XR-ODT (amphetamine) extended-release orally disintegrating tablets, CII Initial U.S. Approval: 196020260506